ANAPTYSBIO, INC. Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-06-29: Form DEF 14A; Period of report 2026-06-29; Description DEF 14A; Document anab-20260629.htm.
- 2025-04-29: Form DEF 14A; Period of report 2025-06-17; Description DEF 14A; Document anab-20250429.htm.
- 2024-04-24: Form DEF 14A; Period of report 2024-06-12; Description DEF 14A; Document proxystatementfy2023_def14a.htm.
- 2023-04-27: Form DEF 14A; Period of report 2023-06-15; Description DEF 14A; Document proxystatementfy2022_def14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-06-29 | DEF 14A | 2026-06-29 | DEF 14A | anab-20260629.htm |
| 2025-04-29 | DEF 14A | 2025-06-17 | DEF 14A | anab-20250429.htm |
| 2024-04-24 | DEF 14A | 2024-06-12 | DEF 14A | proxystatementfy2023_def14a.htm |
| 2023-04-27 | DEF 14A | 2023-06-15 | DEF 14A | proxystatementfy2022_def14a.htm |
| 2022-04-29 | DEF 14A | 2022-06-23 | DEF 14A | proxystatementfy2021.htm |
| 2021-04-26 | DEF 14A | 2021-06-17 | DEF 14A | proxystatementfy2020.htm |
| 2020-04-27 | DEF 14A | 2020-06-19 | DEF 14A | proxystatementfy2019.htm |
| 2019-04-26 | DEF 14A | 2018-12-31 | DEF 14A | proxystatementfy2018.htm |
| 2018-04-26 | DEF 14A | 2018-06-12 | DEF 14A | proxystatementfy2017.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |